AU2019360428B2 - Pyrazole derivatives as H4 antagonist compounds - Google Patents
Pyrazole derivatives as H4 antagonist compounds Download PDFInfo
- Publication number
- AU2019360428B2 AU2019360428B2 AU2019360428A AU2019360428A AU2019360428B2 AU 2019360428 B2 AU2019360428 B2 AU 2019360428B2 AU 2019360428 A AU2019360428 A AU 2019360428A AU 2019360428 A AU2019360428 A AU 2019360428A AU 2019360428 B2 AU2019360428 B2 AU 2019360428B2
- Authority
- AU
- Australia
- Prior art keywords
- methyl
- mmol
- pyrazole
- compound according
- cas
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1817047.2A GB201817047D0 (en) | 2018-10-19 | 2018-10-19 | H4 antagonist compounds |
| GB1817047.2 | 2018-10-19 | ||
| PCT/GB2019/052997 WO2020079457A1 (en) | 2018-10-19 | 2019-10-21 | Pyrazole derivatives as h4 antagonist compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2019360428A1 AU2019360428A1 (en) | 2021-04-29 |
| AU2019360428B2 true AU2019360428B2 (en) | 2024-05-09 |
Family
ID=64453795
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2019360428A Active AU2019360428B2 (en) | 2018-10-19 | 2019-10-21 | Pyrazole derivatives as H4 antagonist compounds |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US12234227B2 (https=) |
| EP (1) | EP3867248B1 (https=) |
| JP (1) | JP7532353B2 (https=) |
| KR (1) | KR102873380B1 (https=) |
| CN (1) | CN113272297B (https=) |
| AU (1) | AU2019360428B2 (https=) |
| BR (1) | BR112021007372A2 (https=) |
| CA (1) | CA3116628A1 (https=) |
| ES (1) | ES3058587T3 (https=) |
| GB (1) | GB201817047D0 (https=) |
| MX (1) | MX2021004280A (https=) |
| SG (1) | SG11202103133QA (https=) |
| WO (1) | WO2020079457A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB202005858D0 (en) * | 2020-04-22 | 2020-06-03 | Heptares Therapeutics Ltd | H4 Antagonist compounds |
| GB202019667D0 (en) * | 2020-12-14 | 2021-01-27 | Heptares Therapeutics Ltd | H4 antagonist comnpounds |
| WO2022203399A1 (ko) * | 2021-03-26 | 2022-09-29 | 주식회사 스탠다임 | 아데노신 a2a 수용체 길항제 및 이의 용도 |
| WO2022232259A1 (en) * | 2021-04-28 | 2022-11-03 | Cornell University | Soluble adenylyl cyclase (sac) inhibitors and uses thereof |
| EP4421067A4 (en) * | 2021-10-19 | 2026-01-14 | Unimatec Co Ltd | PYRAZOLE COMPOUND CONTAINING FLUORIDE AND ITS PRODUCTION PROCESS |
| KR102621694B1 (ko) * | 2022-09-15 | 2024-01-08 | 주식회사 스탠다임 | 아데노신 a2a 수용체 길항제 및 이의 용도 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1103551A1 (en) * | 1998-07-24 | 2001-05-30 | Daiichi Pharmaceutical Co., Ltd. | Pyrazole derivatives and salts thereof |
| WO2005054239A1 (en) * | 2003-12-05 | 2005-06-16 | Bayer Healthcare Ag | 2-aminopyrimidine derivatives |
| WO2007072163A2 (en) * | 2005-12-20 | 2007-06-28 | Pfizer Limited | Pyrimidine derivatives |
| WO2008060766A2 (en) * | 2006-10-02 | 2008-05-22 | Abbott Laboratories | Histamine h4 receptor ligands for use in pain treatment |
| WO2010059658A1 (en) * | 2008-11-20 | 2010-05-27 | Glaxosmithkline Llc | Chemical compounds |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2000169475A (ja) | 1998-07-24 | 2000-06-20 | Dai Ichi Seiyaku Co Ltd | ピラゾ―ル誘導体およびその塩 |
| US20100035863A1 (en) | 2006-09-12 | 2010-02-11 | Ucb Pharma, S.A. | 2 Amino-Pyrimidine Derivatives As H4 Receptor Antagonists, Processes For Preparing Them And Their Use In Pharmaceutical Compositions |
| CL2008000467A1 (es) | 2007-02-14 | 2008-08-22 | Janssen Pharmaceutica Nv | Compuestos derivados de 2-aminopirimidina, moduladores del receptor histamina h4; su procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar un trastorno inflamatorio seleccionado de alegia, asma |
| WO2009068512A1 (en) | 2007-11-30 | 2009-06-04 | Palau Pharma, S. A. | 2 -amino-pyrimidine derivatives as histamine h4 antagonists |
| PE20091524A1 (es) | 2007-12-19 | 2009-09-25 | Palau Pharma Sa | Derivados de 2-aminopirimidina |
| CN101903385B (zh) | 2007-12-21 | 2013-11-06 | 帕劳制药股份有限公司 | 作为组胺h4受体拮抗剂的4-氨基嘧啶衍生物 |
| TW201035078A (en) | 2009-03-20 | 2010-10-01 | Incyte Corp | Substituted heterocyclic compounds |
| MX2012004995A (es) | 2009-10-29 | 2012-10-03 | Sirtris Pharmaceuticals Inc | Piridinas biciclicas y analogos como moduladores de sirtuina. |
| WO2011076878A1 (en) | 2009-12-23 | 2011-06-30 | Palau Pharma, S.A. | Aminoalkylpyrimidine derivatives as histamine h4 receptor antagonists |
| US9580443B2 (en) | 2012-11-16 | 2017-02-28 | Merck Patent Gmbh | Heterocyclic derivatives as modulators of kinase activity |
| US11401255B2 (en) | 2016-07-28 | 2022-08-02 | Mayo Foundation For Medical Education And Research | Small molecule activators of Parkin enzyme function |
-
2018
- 2018-10-19 GB GBGB1817047.2A patent/GB201817047D0/en not_active Ceased
-
2019
- 2019-10-21 US US17/285,776 patent/US12234227B2/en active Active
- 2019-10-21 SG SG11202103133QA patent/SG11202103133QA/en unknown
- 2019-10-21 CN CN201980084053.7A patent/CN113272297B/zh active Active
- 2019-10-21 AU AU2019360428A patent/AU2019360428B2/en active Active
- 2019-10-21 JP JP2021521390A patent/JP7532353B2/ja active Active
- 2019-10-21 ES ES19794235T patent/ES3058587T3/es active Active
- 2019-10-21 EP EP19794235.2A patent/EP3867248B1/en active Active
- 2019-10-21 MX MX2021004280A patent/MX2021004280A/es unknown
- 2019-10-21 KR KR1020217014805A patent/KR102873380B1/ko active Active
- 2019-10-21 CA CA3116628A patent/CA3116628A1/en active Pending
- 2019-10-21 BR BR112021007372-8A patent/BR112021007372A2/pt unknown
- 2019-10-21 WO PCT/GB2019/052997 patent/WO2020079457A1/en not_active Ceased
-
2024
- 2024-09-05 US US18/826,098 patent/US20250115587A1/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1103551A1 (en) * | 1998-07-24 | 2001-05-30 | Daiichi Pharmaceutical Co., Ltd. | Pyrazole derivatives and salts thereof |
| WO2005054239A1 (en) * | 2003-12-05 | 2005-06-16 | Bayer Healthcare Ag | 2-aminopyrimidine derivatives |
| WO2007072163A2 (en) * | 2005-12-20 | 2007-06-28 | Pfizer Limited | Pyrimidine derivatives |
| WO2008060766A2 (en) * | 2006-10-02 | 2008-05-22 | Abbott Laboratories | Histamine h4 receptor ligands for use in pain treatment |
| WO2010059658A1 (en) * | 2008-11-20 | 2010-05-27 | Glaxosmithkline Llc | Chemical compounds |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3867248B1 (en) | 2025-12-10 |
| KR102873380B1 (ko) | 2025-10-23 |
| CA3116628A1 (en) | 2020-04-23 |
| EP3867248A1 (en) | 2021-08-25 |
| CN113272297B (zh) | 2024-03-19 |
| US20250115587A1 (en) | 2025-04-10 |
| WO2020079457A1 (en) | 2020-04-23 |
| US20210300906A1 (en) | 2021-09-30 |
| GB201817047D0 (en) | 2018-12-05 |
| US12234227B2 (en) | 2025-02-25 |
| SG11202103133QA (en) | 2021-05-28 |
| CN113272297A (zh) | 2021-08-17 |
| ES3058587T3 (en) | 2026-03-11 |
| KR20210079318A (ko) | 2021-06-29 |
| JP7532353B2 (ja) | 2024-08-13 |
| MX2021004280A (es) | 2021-05-31 |
| EP3867248C0 (en) | 2025-12-10 |
| JP2022507013A (ja) | 2022-01-18 |
| BR112021007372A2 (pt) | 2021-07-20 |
| AU2019360428A1 (en) | 2021-04-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2019360428B2 (en) | Pyrazole derivatives as H4 antagonist compounds | |
| AU2020250211B2 (en) | Bicyclic heterocycles as fgfr inhibitors | |
| AU2019405925B2 (en) | Substituted pyrazolopyrimidines and substituted purines and their use as ubiquitin-specific-processing protease 1 (USP1) inhibitors | |
| AU2019385905B2 (en) | 9-substituted amino triazolo quinazoline derivatives as adenosine receptor antagonists, pharmaceutical compositions and their use | |
| US10202390B2 (en) | Heteroaryl substituted aminopyridine compounds | |
| ES2908412T3 (es) | Derivados de piperidin-4-IL azetidina como inhibidores de JAK1 | |
| AU2023261809A1 (en) | Pyrimidine compound, method for preparing same, and pharmaceutical use thereof | |
| CA2767097A1 (en) | Pyrazolopyrimidine jak inhibitor compounds and methods | |
| AU2003301226A1 (en) | Acyclic pyrazole compounds for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | |
| US20230219965A1 (en) | Nitrogen-containing fused bicyclic compounds and their use as ubiquitin-specific-processing protease 1 (usp1) inhibitors | |
| AU2011311960A1 (en) | Inhibitors of polo-like kinase | |
| EP2464641A1 (en) | Pyrimidine compounds as tuberculosis inhibitors | |
| AU2022303310A1 (en) | Pyrrolopyridone derivatives useful in the treatment of cancer | |
| TW202502755A (zh) | 酪胺酸激酶2抑制劑及組成物以及其方法 | |
| CN119866338A (zh) | 酪氨酸激酶2抑制剂及其用途 | |
| CN111763217B (zh) | 一类噻吩并氮杂环类化合物、制备方法和用途 | |
| RU2821516C2 (ru) | Пиразольные производные в качестве соединений-антагонистов h4 | |
| CA3180853A1 (en) | H4 antagonist compounds | |
| EP4661875A1 (en) | Compounds and compositions useful as degraders of mk2 kinase |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HB | Alteration of name in register |
Owner name: NXERA PHARMA UK LIMITED Free format text: FORMER NAME(S): HEPTARES THERAPEUTICS LIMITED |
|
| FGA | Letters patent sealed or granted (standard patent) |